ArticleFuture science OA2025
Clinicopathologic and prognostic significance of TIAM2 overexpression in resected hepatocellular carcinoma.
Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinicopathologic and prognostic significance of T-cell lymphoma invasion and metastasis 2 (TIAM2) in hepatocellular carcinoma (HCC) remains unclear.
methodsTIAM2 expression was detected immunohistochemically in matched HCC and adjacent liver (AL) specimens from 168 patients with radical resection. The correlations between TIAM2 and clinicopathologic parameters, overall and disease-free survival were evaluated. The expression, prognostic value and genomic alterations of
resultsTIAM2 was significantly overexpressed in HCC tissues, compared with AL tissues (
conclusionsTIAM2 overexpression closely correlated with tumor multiplicity and poor prognosis in resected HCC, thus being a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.